Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 473,800 shares, a growth of 136.2% from the September 30th total of 200,600 shares. Currently, 14.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 368,100 shares, the days-to-cover ratio is presently 1.3 days.

Analyst Upgrades and Downgrades

Separately, Benchmark reiterated a “buy” rating and set a $7.00 price target on shares of Biofrontera in a research report on Friday, August 16th.

Biofrontera Stock Performance

Shares of BFRI stock traded down $0.06 on Friday, hitting $0.91. 43,484 shares of the company’s stock traded hands, compared to its average volume of 378,697. The stock has a market capitalization of $4.62 million, a price-to-earnings ratio of -0.07 and a beta of 0.50. The company’s fifty day simple moving average is $1.09 and its 200 day simple moving average is $1.18. Biofrontera has a one year low of $0.61 and a one year high of $5.28.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.07. Biofrontera had a negative return on equity of 837.97% and a negative net margin of 38.34%. The firm had revenue of $7.84 million for the quarter, compared to the consensus estimate of $9.02 million. As a group, sell-side analysts anticipate that Biofrontera will post -3.11 earnings per share for the current fiscal year.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.